Skip to main content
Learn How to Analyze Your Market and Trading Plan
Custom-design an options strategy to fit your market outlook. This guide goes beyond the basics to help you understand how to evaluate a strategy’s risk and reward. Start with your market outlook, then hone in on your strategy based on the risk you’re willing to take.
Download Your FREE Options Trading Strategy Guide today!
pixel

POAI Insider Trading (Predictive Oncology)

Insider Ownership Percentage: 10.35%
Insider Buying (Last 12 Months): $3,600.00
Insider Selling (Last 12 Months): $544.00

Predictive Oncology Insider Trading History Chart

Predictive Oncology Share Price & Price History

$0.87
▲ +0.03 (3.58%)
As of 05/14/2021 01:00 AM ET
Days: 30 | 90 | 365
Gain the Knowledge You Need to Successfully Trade Futures Markets
Our Technical Analysis Guide will give you the insight into today’s fast-moving markets. It’s designed to give you a head start in learning the basics of various TA tools and techniques.
Download Your Complimentary Technical Analysis Guide TODAY!
pixel

Predictive Oncology Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/22/2020Carl I SchwartzCEOSell640$0.85$544.001,611,341View SEC Filing Icon  
9/1/2020Richard L GabrielDirectorBuy4,000$0.90$3,600.0012,070View SEC Filing Icon  
9/5/2019Richard L GabrielDirectorBuy2,000$0.46$920.00
8/23/2019Richard L GabrielDirectorBuy3,000$0.60$1,800.00View SEC Filing Icon  
5/24/2019Carl I SchwartzCEOBuy100,000$0.56$56,000.00View SEC Filing Icon  
12/11/2018Richard L GabrielDirectorBuy2,000$0.68$1,360.00View SEC Filing Icon  
11/28/2018Richard L GabrielDirectorBuy2,000$0.78$1,560.00View SEC Filing Icon  
11/20/2018Richard L GabrielDirectorBuy1,000$0.89$890.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Predictive Oncology (NASDAQ:POAI)

2.00% of Predictive Oncology stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Predictive Oncology Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/13/2021Renaissance Technologies LLC593,267$0.72M0.0%N/A1.191%Search for SEC Filing on Google Icon
5/13/2021Bank of New York Mellon Corp37,348$45K0.0%N/A0.075%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp67,289$81K0.0%+343.4%0.135%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC138,973$0.17M0.0%N/A0.279%Search for SEC Filing on Google Icon
5/11/2021Maryland Capital Management46,000$56K0.0%N/A0.092%Search for SEC Filing on Google Icon
8/14/2020Sabby Management LLC223,540$0.37M0.1%N/A1.541%Search for SEC Filing on Google Icon
8/12/2020Bank of New York Mellon Corp49,449$81K0.0%+191.7%0.341%Search for SEC Filing on Google Icon
8/7/2020Virtu Financial LLC22,668$37K0.0%N/A0.156%Search for SEC Filing on Google Icon
7/17/2020Csenge Advisory Group17,500$29K0.0%N/A0.133%Search for SEC Filing on Google Icon
5/6/2020Bank of New York Mellon Corp16,953$27K0.0%N/A0.274%Search for SEC Filing on Google Icon
8/14/2019Vanguard Group Inc.155,934$0.12M0.0%N/A0.508%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Predictive Oncology logo
Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company operates in three segments: Helomics, Soluble, and Skyline. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers STREAMWAY System, a wall-mounted fully automated system that disposes suction fluid providing uninterrupted performance for physicians while virtually eliminating healthcare workers' exposure to infectious fluids collected during surgical and other patient procedures, as well as proprietary cleaning fluid and filters to users of its systems. The company also provides contract research organization (CRO) and AI-driven predictive models of tumor drug response to improve clinical outcomes to assist pharmaceutical, diagnostic, and biotech industries; and soluble and stable formulations for proteins, including vaccines, antibodies, and other protein therapeutics, as well as develops tumor models for precision cancer therapy and drug development. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence (AI) applied to diseases databases. The company sells its medical device products directly to hospitals and other medical facilities through employed sales representatives, independent contractors, and distributors. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
Read More on Predictive Oncology

Today's Range

Now: $0.87
$0.85
$0.90

50 Day Range

MA: $1.17
$0.84
$1.49

52 Week Range

Now: $0.87
$0.63
$2.30

Volume

1,145,070 shs

Average Volume

4,075,066 shs

Market Capitalization

$43.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67

Who are the company insiders with the largest holdings of Predictive Oncology?

Predictive Oncology's top insider investors include:
  1. Carl I Schwartz (CEO)
  2. Richard L Gabriel (Director)

Who are the major institutional investors of Predictive Oncology?

Predictive Oncology's top institutional investors include:
  1. Renaissance Technologies LLC — 1.19%
  2. Geode Capital Management LLC — 0.28%
  3. Northern Trust Corp — 0.14%
  4. Maryland Capital Management — 0.09%
  5. Bank of New York Mellon Corp — 0.07%

Which major investors are buying Predictive Oncology stock?

In the last quarter, POAI stock was bought by institutional investors including:
  1. Renaissance Technologies LLC
  2. Geode Capital Management LLC
  3. Northern Trust Corp
  4. Maryland Capital Management
  5. Bank of New York Mellon Corp
Within the previous year, these company insiders have bought Predictive Oncology stock:
  1. Carl I Schwartz (CEO)
  2. Richard L Gabriel (Director)
Gain the Knowledge You Need to Successfully Trade Futures Markets
Our Technical Analysis Guide will give you the insight into today’s fast-moving markets. It’s designed to give you a head start in learning the basics of various TA tools and techniques.
Download Your Complimentary Technical Analysis Guide TODAY!
pixel